The information supports Agency
guidance intended to assist applicants in developing labeling for
outcome claims for drugs that are indicated to treat hypertension.
The appropriate use of these drugs can be encouraged by making the
connection between lower blood pressure and improved cardiovascular
outcomes more explicit in labeling.
The information collection
reflects an increase of 80 annual hours and 3 annual submissions
that corresponds with supplemental labeling claim submissions we
have received since last approval of the information collection. We
have also uploaded reported costs associated with the information
collection so that they appear on omb.report to assist
readers.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.